Ozempic: Beyond Weight Loss, May Reduce Epilepsy Risk

• A new study suggests GLP-1 medications, like Ozempic, may reduce epilepsy risk in Type 2 diabetes patients.
• The analysis of over 450,000 US adults found GLP-1 users were 16% less likely to develop epilepsy than those on DPP-4 inhibitors.
• Semaglutide, the active ingredient in Ozempic, showed the strongest association with a reduced risk of epilepsy.
• The research, published in Neurology, is observational, indicating a link but not proving causation.
• Further randomized, long-term trials are needed to confirm these preliminary findings.

Why It Matters: Ozempic may reduce epilepsy risk, expanding its health benefits.